Literature DB >> 9386657

Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus.

F Mosca1, M Bray, M Lattanzio, M Fumagalli, C Tosetto.   

Abstract

OBJECTIVE: To compare the effects on cerebral perfusion and oxygenation of intravenous ibuprofen and indomethacin as treatment for patent ductus arteriosus in preterm infants. STUDY
DESIGN: Sixteen infants receiving mechanical ventilation (< 31 weeks gestation) with patent ductus arteriosus received either 0.2 mg/kg indomethacin (n = 8) or 10 mg/kg ibuprofen (n = 8) infused over 1 minute. Near-infrared spectroscopy was used to measure changes in cerebral blood volume and in oxidized cytochrome oxidase concentration. Cerebral blood flow velocity in the pericallosal artery was measured using Doppler ultrasonography.
RESULTS: Indomethacin caused a significant reduction of CBV (maximal changes in cerebral blood volume: -320 +/- 171 microL/100 gm) and, in four of eight patients, a fall in oxidized cytochrome oxidase concentration (maximal change in oxidized cytochrome oxidase concentration in the eight patients: -0.68 +/- 0.98 mumol/L, NS). Cerebral blood flow velocity fell significantly. Ibuprofen caused no significant reduction of cerebral blood volume, oxidized cytochrome oxidase concentration, or cerebral blood flow velocity, whereas a significant increase of cerebral blood volume (+207 +/- 200 microL/100 gm) was observed after 60 minutes. Ductus closure was seen in six of eight infants after the first dose of indomethacin and in five of eight infants after the first dose of ibuprofen. The therapeutic cycle involved administration of a second and third dose, provided no side effects occurred. Treatment was effective in all infants.
CONCLUSION: Compared with indomethacin, treatment with ibuprofen does not significantly reduce cerebral perfusion and oxygen availability; the observed increase in cerebral blood volume requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9386657     DOI: 10.1016/s0022-3476(97)70060-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  47 in total

Review 1.  Patent ductus arteriousus in the premature neonate: current concepts in pharmacological management.

Authors:  C Hammerman; M Kaplan
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

2.  Improved closure of patent ductus arteriosus with high doses of ibuprofen.

Authors:  Udo Meißner; Raktima Chakrabarty; Hans-Georg Topf; Wolfgang Rascher; Michael Schroth
Journal:  Pediatr Cardiol       Date:  2012-02-04       Impact factor: 1.655

3.  Conservative treatment for patent ductus arteriosus in the preterm.

Authors:  Sophie Vanhaesebrouck; Inge Zonnenberg; Piet Vandervoort; Els Bruneel; Marie-Rose Van Hoestenberghe; Claire Theyskens
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-01-09       Impact factor: 5.747

4.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2019-06-21

Review 5.  A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.

Authors:  Ronald L Thomas; Graham C Parker; Bart Van Overmeire; Jacob V Aranda
Journal:  Eur J Pediatr       Date:  2004-12-10       Impact factor: 3.183

6.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-01-27

7.  Patent ductus arteriosus: an overview.

Authors:  James E Dice; Jatinder Bhatia
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

8.  Clinical experience with intravenous Ibuprofen lysine in the pharmacologic closure of patent ductus arteriosus.

Authors:  Evelyn R Hermes-Desantis; Jacob V Aranda
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

Review 9.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

10.  Near-infrared spectroscopy for detection of a significant patent ductus arteriosus.

Authors:  Valerie Y Chock; Laura A Rose; Jeanet V Mante; Rajesh Punn
Journal:  Pediatr Res       Date:  2016-09-07       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.